TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30700619

Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus infusion (PIBI) of 0.2% ropivacaine at 8 mL/h
Number of subjects: 34

Group type: COMPARATOR
Intervention: Continuous infusion (CI) of 0.2% ropivacaine at 8 mL/h
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus infusion (PIBI) of 0.2% ropivacaine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Continuous infusion (CI) of 0.2% ropivacaine
Number of subjects: 34
Study: 28728281

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes individuals
Number of subjects: 1719

Group type: EXPERIMENTAL
Intervention: Age, duration of diabetes, education, fasting blood glucose, ocular axial length
Number of subjects: 1719
Study: 26084322

Group type: EXPERIMENTAL
Intervention: Robotic/virtually simulated activity (VR) group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional, repetitive task practice (RTP) group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 23886842

Group type: EXPERIMENTAL
Intervention: PFIT-s (Physical Function ICU Test - scored)
Number of subjects: 144
Study: 21289455

Group type: EXPERIMENTAL
Intervention: Hamstring-injured group (HG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study: 19784470

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate ointment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15682244

Group type: EXPERIMENTAL
Intervention: Standard dose cotrimoxazole (4 mg trimethoprim plus 20 mg sulfamethoxazole/kg)
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Double dose cotrimoxazole (8 mg trimethoprim plus 40 mg sulfamethoxazole/kg)
Number of subjects: 1143
Study: 12692782

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation (IAD) therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Continuous androgen deprivation (CAD) therapy
Number of subjects: 80
Study: 10594485

Group type: EXPERIMENTAL
Intervention: 600 mg TA orally
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3.5 mg glibenclamide orally
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 600 mg TA+3.5 mg glibenclamide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 600 mg TA+50 mg acarbose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 24
Study: 9569805

Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Local metronidazole treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Systemic metronidazole treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Local metronidazole combined with scaling and root planing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Systemic metronidazole combined with scaling and root planing
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study: 1812314

Group type: EXPERIMENTAL
Intervention: tannalbuminate (500 mg) and ethacridin‐lactate (50 mg), 1 tbl. b.i.d.
Number of subjects: 77

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: tannalbuminate and ethacridin‐lactate
Number of subjects: 77
Study: 6871776

Group type: EXPERIMENTAL
Intervention: Intraaortic protamine (3 mg . Kg‐1 injected over 30 sec)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous protamine (3 mg . Kg‐1 injected over 30 sec)
Number of subjects: 10
Study: 30540966

Group type: EXPERIMENTAL
Intervention: Perioperative immunonutrition (oral supplementation enriched with arginine, ω‐3 fatty acids, and dietary nucleotides)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preoperative immunonutrition (same enriched formula before surgery and standard enteral nutrition following surgery)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Perioperative immunonutrition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preoperative immunonutrition
Number of subjects: 60
Study: 28885466

Group type: EXPERIMENTAL
Intervention: Perceived Deficits Questionnaire (PDQ)
Number of subjects: 183
Study: 26218009

Group type: EXPERIMENTAL
Intervention: Simulation before clinical experience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation after clinical experience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical experience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation (timing not specified)
Number of subjects: 0
Study: 24052490

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (2 mg/24 h) applied daily for 3 days
Number of subjects: 17
Study: 21909730

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D(3) 6,500 IU/day (20,000 IU twice per week + 800 IU/day)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Standard-dose vitamin D(3) 800 IU/day (placebo twice per week + 800 IU/day)
Number of subjects: 297
Study: 19650844

Group type: EXPERIMENTAL
Intervention: dobutamine (2.5 microg x kg(‐1) x min(‐1))
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: dopexamine (1 microg x kg(‐1) x min(‐1))
Number of subjects: 11
Study: 17956827

Group type: EXPERIMENTAL
Intervention: Once-daily LPV/r, tenofovir (TDF), and lamivudine (3TC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control arm (existing regimen)
Number of subjects: 72
Study: 15885349

Group type: EXPERIMENTAL
Intervention: Citalopram (20mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: IFN-alpha treatment without pre-emptive antidepressant therapy
Number of subjects: 14
Study: 12360839

Group type: EXPERIMENTAL
Intervention: Stress management program consisting of twenty 2-hr group sessions over 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9793810

Group type: EXPERIMENTAL
Intervention: Alfentanil 5 micrograms/kg i.v.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine 1 mg/kg i.v.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline) i.v.
Number of subjects: 60
Study: 8520195

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 12

Group type: COMPARATOR
Intervention: SUZI
Number of subjects: 12
Study: 11527130

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of Bisoprolol and Nifedipine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 370526

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methyl testosterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31300029

Group type: EXPERIMENTAL
Intervention: Preferred intensity exercise (3 sessions/week for 4 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Prescribed intensity exercise (3 sessions/week for 4 weeks)
Number of subjects: 38
Study: 28806095

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections at 7 and 14 days post-surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no PRP injections)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 60
Study: 26138715

Group type: EXPERIMENTAL
Intervention: SocialVille training program
Number of subjects: 128

Group type: COMPARATOR
Intervention: Active control computer game condition
Number of subjects: 128
Study: 23782553

Group type: EXPERIMENTAL
Intervention: predictD‐CCRT intervention (personalized intervention by family physicians)
Number of subjects: 3286

Group type: COMPARATOR
Intervention: usual care (control group)
Number of subjects: 3286

Group type: EXPERIMENTAL
Intervention: predictD‐CCRT intervention
Number of subjects: 3286
Study: 22282958

Group type: EXPERIMENTAL
Intervention: IBN/SNAC formulation co-administered with metformin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 22
Study: 19761951

Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy plus massage therapy (20 min sessions, once per week for 6 weeks)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Group Interpersonal Psychotherapy (1h sessions, once per week for 6 weeks)
Number of subjects: 112
Study: 16386341

Group type: EXPERIMENTAL
Intervention: Tenderfoot
Number of subjects: 340

Group type: COMPARATOR
Intervention: Genie Lancet
Number of subjects: 340
Study: 12000205

Group type: EXPERIMENTAL
Intervention: Aerobic exercise with bright light (2500-4000 lux)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Aerobic exercise with normal illumination
Number of subjects: 98

Group type: COMPARATOR
Intervention: Relaxation/stretching sessions in bright light
Number of subjects: 98
Study: 10460375

Group type: EXPERIMENTAL
Intervention: Iodixanol (270 mg I/ml)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iohexol (300 mg I/ml)
Number of subjects: 100
Study: 7599293

Group type: EXPERIMENTAL
Intervention: Growth hormone 0.2 IU
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Growth hormone 0.7 IU
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Growth hormone 0.02 IU
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Growth hormone 2 IU
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (vehicle) in group 3
Number of subjects: 36
Study: 2296215

Group type: EXPERIMENTAL
Intervention: Cost-containment educational program involving senior physicians, lectures, comparative feedback, chart reviews, and small group discussions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group interns (not specified how they were educated or trained).
Number of subjects: 0
Study: 675728

Group type: EXPERIMENTAL
Intervention: Sonographic examination (grey scale)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Lymphographic examination
Number of subjects: 51
Study: 29526833

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose (LD) 24 hours after the last maintenance dose (MD) of ticagrelor (C-600 mg-24h)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose (LD) 12 hours after the last maintenance dose (MD) of ticagrelor (C-600 mg-12h)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d maintenance dose (C-75 mg-24h)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily maintenance dose (T-90 mg twice daily)
Number of subjects: 80
Study: 27676149

Group type: EXPERIMENTAL
Intervention: Cluster set configurations
Number of subjects: 10
Study: 25330838

Group type: EXPERIMENTAL
Intervention: Transcranial bright light treatment via ear canals (1 lumen/0.72 mW/cm(2))
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Transcranial bright light treatment via ear canals (4 lumens/2.881 mW/cm(2))
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Transcranial bright light treatment via ear canals (9 lumens/6.482 mW/cm(2))
Number of subjects: 89
Study: 23185073

Group type: EXPERIMENTAL
Intervention: V-Loc 90 barbed sutures
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional 3-layer closure with nonbarbed sutures
Number of subjects: 30
Study: 21108056

Group type: EXPERIMENTAL
Intervention: 800 ml of 12.5% glucose solution the night before surgery and 200 ml two hours before surgery (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water instead of glucose (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fasting for 8‐12 hours before operation (Group C)
Number of subjects: 60
Study: 19143586

Group type: EXPERIMENTAL
Intervention: EPP's lay-led skills training
Number of subjects: 0
Study: 15745775

Group type: EXPERIMENTAL
Intervention: gatifloxacin 0.3%
Number of subjects: 52
Study: 12357299

Group type: EXPERIMENTAL
Intervention: 30 mg EPI/30 ml saline 19 times over 1 year (arm A)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 30 mg EPI/30 ml 12 times over 5 months (arm B)
Number of subjects: 125
Study: 9796041

Group type: EXPERIMENTAL
Intervention: DTaP or DTP vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pertactin value < 7 EU ml‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pertactin value >= 7 EU ml‐1 and PT value >= 66 EU ml‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pertactin value >= 7 EU ml‐1 and PT value < 66 EU ml‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High versus low pertactin values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of antibody to pertactin, PT and fimbriae‐2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicomponent vaccines containing pertactin and fimbriae
Number of subjects: 0
Study: 7636684

Group type: EXPERIMENTAL
Intervention: Rice-based oral rehydration solution (50 g/L)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Glucose-based WHO/UNICEF solution
Number of subjects: 100
Study: 2613606

Group type: EXPERIMENTAL
Intervention: Norfloxacin plus amphotericin-B
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ceftazidime (monotherapy)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus tobramycin (combination therapy)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus piperacillin
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin
Number of subjects: 34
Study: 19807

Group type: EXPERIMENTAL
Intervention: Naloxone 1.2 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31835096

Group type: EXPERIMENTAL
Intervention: Assert intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 31669625

Group type: EXPERIMENTAL
Intervention: Anagliptin (200 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metformin (1000 mg/day)
Number of subjects: 24
Study: 27342581

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: High serum sclerostin (sScl)
Number of subjects: 396
Study: 25627123

Group type: EXPERIMENTAL
Intervention: Split-thickness autograft combined with harvested skin cell suspension
Number of subjects: 88

Group type: COMPARATOR
Intervention: Split-thickness autograft alone (Control)
Number of subjects: 88
Study: 24318319

Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 80

Group type: COMPARATOR
Intervention: AMBI sliding hip screw
Number of subjects: 80
Study: 22463757

Group type: EXPERIMENTAL
Intervention: Technology-enhanced learning (TEL) group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional face-to-face group
Number of subjects: 42
Study: 19119028

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: No Statins
Number of subjects: 213
Study: 17440685

Group type: EXPERIMENTAL
Intervention: 2-3 drops of 5% povidone iodine (drops group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 10 ml flush of 5% povidone iodine (flush group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 28
Study: 15383800

Group type: EXPERIMENTAL
Intervention: Alvimopan 6 mg
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study: 11297484

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 549
Study: 9671379

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 35

Group type: COMPARATOR
Intervention: Hypertonic saline
Number of subjects: 35
Study: 8005548

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) plus ethinyl estradiol (EE)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 17
Study: 29775015

Group type: EXPERIMENTAL
Intervention: Percutaneous Dilatation Tracheostomy (PDT)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Traditional Tracheostomy (TT)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: PDT
Number of subjects: 1200
Study: 27814738

Group type: EXPERIMENTAL
Intervention: Organisational support only (Group ORG)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Organisational support plus LUMOback activity tracker (Group ORG + Tracker)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (Group ORG)
Number of subjects: 153
Study: 25437483

Group type: EXPERIMENTAL
Intervention: Accelerated corneal cross-linking
Number of subjects: 153

Group type: COMPARATOR
Intervention: Conventional corneal cross-linking
Number of subjects: 153
Study: 23359581

Group type: EXPERIMENTAL
Intervention: Take Care technique (early surfactant treatment via thin catheter)
Number of subjects: 200

Group type: COMPARATOR
Intervention: InSurE technique (intubation, surfactant instillation, positive pressure ventilation)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Take Care technique
Number of subjects: 200
Study: 20592122

Group type: EXPERIMENTAL
Intervention: Paired-pulse transcranial magnetic stimulation (ppTMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-pulse transcranial magnetic stimulation (spTMS)
Number of subjects: 0
Study: 19395578

Group type: EXPERIMENTAL
Intervention: 3 mg/kg infliximab
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 3 mg/kg infliximab and 5 mg/kg infliximab
Number of subjects: 130
Study: 16984575

Group type: EXPERIMENTAL
Intervention: Graftjacket tissue matrix plus mineral oil-soaked fluff compression dressing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Wound gel with gauze dressings
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Graftjacket tissue matrix
Number of subjects: 28
Study: 12764908

Group type: EXPERIMENTAL
Intervention: Tetramethylpyrazine (TMP) 3 mg/kg intravenously after anesthesia induction and 1 mg/kg in oxygenator during CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no TMP treatment)
Number of subjects: 30
Study: 11015087

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass graft (OP-CAB) procedures
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting procedures
Number of subjects: 100
Study: 9336104

Group type: EXPERIMENTAL
Intervention: Keyswitch make force of 1.02 N
Number of subjects: 10

Group type: COMPARATOR
Intervention: Keyswitch make force of 0.47 N
Number of subjects: 10

Group type: COMPARATOR
Intervention: Keyswitch make force of 0.34 N
Number of subjects: 10
Study: 8103650

Group type: EXPERIMENTAL
Intervention: Org 9487 without neostigmine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Org 9487 with neostigmine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 45
Study: 3079625

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 346

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 346
Study: 31388990

Group type: EXPERIMENTAL
Intervention: Cholera vaccination
Number of subjects: 73000
Study: 30096265

Group type: EXPERIMENTAL
Intervention: Xenon phototherapy of the stellate ganglion (XPSG)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham treatment (non-XPSG)
Number of subjects: 43
Study: 25800863

Group type: EXPERIMENTAL
Intervention: Integrated Stress Management Program (ISMP), 8 sessions of 2 hours each over 4 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study: 24746263

Group type: COMPARATOR
Intervention: Written advice (control)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Brief GP advice (written advice plus GP advice on physical activity)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Brief GP advice plus a pedometer to self-monitor physical activity
Number of subjects: 131
Study: 22574757

Group type: EXPERIMENTAL
Intervention: Stepped care intervention programme
Number of subjects: 176

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 176
Study: 20931823

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral anticoagulants
Number of subjects: 50
Study: 18291584

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) for 25 minutes
Number of subjects: 55

Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 55
Study: 16204713

Group type: EXPERIMENTAL
Intervention: Rapid scanning protocol (4 min total: 3 min emission, 1 min transmission)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional scanning protocol (20 min total: 10 min emission, 10 min transmission)
Number of subjects: 105
Study: 12127464

Group type: EXPERIMENTAL
Intervention: Standard outpatient alcoholism treatment (ST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal treatment (MT)
Number of subjects: 0
Study: 10403865

Group type: EXPERIMENTAL
Intervention: Ambulation (spending at least 20 min of every hour out of bed)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Staying in bed
Number of subjects: 229
Study: 7586434

Group type: EXPERIMENTAL
Intervention: Warm bypass (31.8 +/‐ 0.4 degrees C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cold bypass (26.3 +/‐ 0.5 degrees C)
Number of subjects: 20
Study: 1693111

Group type: EXPERIMENTAL
Intervention: Otomize (neomycin/dexamethasone spray)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sofradex (framycetin/gramicidin/dexamethasone drops)
Number of subjects: 60
Study: 6988936

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 31269025

Group type: EXPERIMENTAL
Intervention: SPG stimulation
Number of subjects: 98

Group type: COMPARATOR
Intervention: NINDS rt-PA trial placebo patients
Number of subjects: 98
Study: 28630183

Group type: EXPERIMENTAL
Intervention: SDF variant 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SDF variant 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional formulation
Number of subjects: 0
Study: 26423050

Group type: EXPERIMENTAL
Intervention: 20 mL mepivacaine 1.5%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 30 mL mepivacaine 1%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 30 mL mepivacaine 1.5%
Number of subjects: 45
Study: 23551510

Group type: EXPERIMENTAL
Intervention: ProTaper™ rotary system
Number of subjects: 20

Group type: COMPARATOR
Intervention: ProTaper Universal™ rotary system
Number of subjects: 20